Trellus Health plc had signed a renewal of its Licensing Agreement with Pfizer Inc. Under the renewed agreement, Pfizer will continue to license Trellus Health's patient support educational content for inclusion within its inflammatory bowel disease digital application. The original agreement was entered into in the second quarter of 2024. As previously announced, the Company has reduced its monthly cash burn to an average of $300,000 as of March 2026.
With this renewal, as well as a loan from Laurie Keefer, Ph.D., the Company's scientific co-founder and co-inventor of the Company's resilience methodology, the Company expects its cash runway to extend into May 2026. The Board remains supportive of the Company's commercial strategy and is engaged in ongoing discussions regarding a range of potential funding options to further extend the Company's cash runway.
